Clinical Trial Update: A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy [Phase 1]

View source ↗

Summary

A Phase I/III clinical study evaluating NouvNeu001 Injection for Multiple System Atrophy (MSA), with Phase 1 currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• NouvNeu001 Injection

Snippet

Sponsor: iRegene Therapeutics Co., Ltd. | Conditions: Multiple System Atrophy - Parkinsonian Subtype (MSA-P) | Phase 1 | Status: RECRUITING